Therefore, the aim of this study was to assess, for the first time, the contribution of the formation of the Bcl-2 and beclin-1 complex in the context of the glioma cell elimination through programmed cell death induction using the combined action of LY294002 and sorafenib. This evidence concerns the gene BECN1 and glioma.